CircFAM64A enhances cellular processes in triple-negative breast cancer by targeting the miR-149-5p/CDT1 axis

Yusufu Maimaiti1,2, Ning Zhang1, Yunke Zhang1

  • 1Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Environmental Toxicology
|January 20, 2022
PubMed

Insights

Circular RNA FAM64A (circFAM64A) is upregulated in triple-negative breast cancer (TNBC), promoting tumor growth and spread. It acts by sponging miR-149-5p, leading to increased expression of CDT1, a poor prognostic marker.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapies.
  • Circular RNAs (circRNAs) are implicated in cancer development.
  • The role of circFAM64A in TNBC is not well understood.

Purpose of the Study:

  • To investigate the expression and function of circFAM64A in TNBC.
  • To elucidate the underlying molecular mechanism of circFAM64A in TNBC progression.

Main Methods:

  • Bioinformatic analysis of GEO dataset (GSE101124).
  • RT-qPCR, Western blot, cell proliferation, migration, invasion, and cell cycle assays.
  • RNA immunoprecipitation (RIP), RNA pulldown, and luciferase reporter assays.

Main Results:

  • CircFAM64A expression is significantly upregulated in TNBC tissues and cells.
  • Overexpression of circFAM64A enhances TNBC cell proliferation, migration, invasion, and cell cycle progression.
  • CircFAM64A acts as a molecular sponge for miR-149-5p, increasing CDT1 expression, which is linked to poor prognosis.

Conclusions:

  • CircFAM64A plays a crucial oncogenic role in TNBC.
  • The circFAM64A/miR-149-5p/CDT1 axis promotes TNBC progression.
  • CircFAM64A represents a potential therapeutic target for TNBC.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K